一项诉讼要求Savara误导投资者 说毒品有缺陷 损害了股票价值 A lawsuit claims Savara misled investors about its drug's flaws, hurting stock value.

2025年10月5日对Savara Inc.(SVRA)提起了集体诉讼,指控该公司在2024年3月4日至2025年5月23日期间误导投资者,未披露其MOLBREEVI药物应用的重大缺陷,包括关于化学、制造和控制的数据不足。 A class action lawsuit has been filed against Savara Inc. (SVRA) on October 5, 2025, alleging the company misled investors from March 4, 2024, to May 23, 2025, by failing to disclose critical flaws in its MOLBREEVI drug application, including insufficient data on chemistry, manufacturing, and controls. 投诉声称这些遗漏使得FDA批准不太可能, 延迟监管提交,增加需要更多资本的风险, The complaint claims these omissions made FDA approval unlikely, delayed regulatory submission, increased the risk of needing more capital, and artificially inflated the stock price, causing financial harm. 该案由Levi & Korsinsky LLP处理,要求根据联邦证券法为受影响的股东追讨赔偿,没有费用,也没有义务参与。 The case, handled by Levi & Korsinsky LLP, seeks recovery for affected shareholders under federal securities laws, with no cost or obligation to participate.